IBDEI2A9 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,38729,1,4,0)
 ;;=4^R60.0
 ;;^UTILITY(U,$J,358.3,38729,2)
 ;;=^5019532
 ;;^UTILITY(U,$J,358.3,38730,0)
 ;;=L53.0^^151^1898^13
 ;;^UTILITY(U,$J,358.3,38730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38730,1,3,0)
 ;;=3^Erythema Toxic
 ;;^UTILITY(U,$J,358.3,38730,1,4,0)
 ;;=4^L53.0
 ;;^UTILITY(U,$J,358.3,38730,2)
 ;;=^5009207
 ;;^UTILITY(U,$J,358.3,38731,0)
 ;;=L53.1^^151^1898^8
 ;;^UTILITY(U,$J,358.3,38731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38731,1,3,0)
 ;;=3^Erythema Annulare Centrifugum
 ;;^UTILITY(U,$J,358.3,38731,1,4,0)
 ;;=4^L53.1
 ;;^UTILITY(U,$J,358.3,38731,2)
 ;;=^5009208
 ;;^UTILITY(U,$J,358.3,38732,0)
 ;;=L51.9^^151^1898^11
 ;;^UTILITY(U,$J,358.3,38732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38732,1,3,0)
 ;;=3^Erythema Multiforme,Unspec
 ;;^UTILITY(U,$J,358.3,38732,1,4,0)
 ;;=4^L51.9
 ;;^UTILITY(U,$J,358.3,38732,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,38733,0)
 ;;=L12.35^^151^1898^7
 ;;^UTILITY(U,$J,358.3,38733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38733,1,3,0)
 ;;=3^Epidermolysis Bullosa,Acquired
 ;;^UTILITY(U,$J,358.3,38733,1,4,0)
 ;;=4^L12.35
 ;;^UTILITY(U,$J,358.3,38733,2)
 ;;=^5009100
 ;;^UTILITY(U,$J,358.3,38734,0)
 ;;=L52.^^151^1898^12
 ;;^UTILITY(U,$J,358.3,38734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38734,1,3,0)
 ;;=3^Erythema Nodosum
 ;;^UTILITY(U,$J,358.3,38734,1,4,0)
 ;;=4^L52.
 ;;^UTILITY(U,$J,358.3,38734,2)
 ;;=^42065
 ;;^UTILITY(U,$J,358.3,38735,0)
 ;;=L49.0^^151^1898^24
 ;;^UTILITY(U,$J,358.3,38735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38735,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ < 10% Body Surface
 ;;^UTILITY(U,$J,358.3,38735,1,4,0)
 ;;=4^L49.0
 ;;^UTILITY(U,$J,358.3,38735,2)
 ;;=^5009190
 ;;^UTILITY(U,$J,358.3,38736,0)
 ;;=L49.1^^151^1898^15
 ;;^UTILITY(U,$J,358.3,38736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38736,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
 ;;^UTILITY(U,$J,358.3,38736,1,4,0)
 ;;=4^L49.1
 ;;^UTILITY(U,$J,358.3,38736,2)
 ;;=^5009191
 ;;^UTILITY(U,$J,358.3,38737,0)
 ;;=L49.2^^151^1898^16
 ;;^UTILITY(U,$J,358.3,38737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38737,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 20-29% Body Surface
 ;;^UTILITY(U,$J,358.3,38737,1,4,0)
 ;;=4^L49.2
 ;;^UTILITY(U,$J,358.3,38737,2)
 ;;=^5009192
 ;;^UTILITY(U,$J,358.3,38738,0)
 ;;=L49.3^^151^1898^17
 ;;^UTILITY(U,$J,358.3,38738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38738,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 30-39% Body Surface
 ;;^UTILITY(U,$J,358.3,38738,1,4,0)
 ;;=4^L49.3
 ;;^UTILITY(U,$J,358.3,38738,2)
 ;;=^5009193
 ;;^UTILITY(U,$J,358.3,38739,0)
 ;;=L49.4^^151^1898^18
 ;;^UTILITY(U,$J,358.3,38739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38739,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 40-49% Body Surface
 ;;^UTILITY(U,$J,358.3,38739,1,4,0)
 ;;=4^L49.4
 ;;^UTILITY(U,$J,358.3,38739,2)
 ;;=^5009194
 ;;^UTILITY(U,$J,358.3,38740,0)
 ;;=L49.5^^151^1898^19
 ;;^UTILITY(U,$J,358.3,38740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38740,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 50-59% Body Surface
 ;;^UTILITY(U,$J,358.3,38740,1,4,0)
 ;;=4^L49.5
 ;;^UTILITY(U,$J,358.3,38740,2)
 ;;=^5009195
 ;;^UTILITY(U,$J,358.3,38741,0)
 ;;=L49.6^^151^1898^20
 ;;^UTILITY(U,$J,358.3,38741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38741,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 60-69% Body Surface
 ;;^UTILITY(U,$J,358.3,38741,1,4,0)
 ;;=4^L49.6
 ;;^UTILITY(U,$J,358.3,38741,2)
 ;;=^5009196
 ;;^UTILITY(U,$J,358.3,38742,0)
 ;;=L49.7^^151^1898^21
